Skip to content
Open access

Usability and relevance of specialized population-based cancer registry data in externally controlled trials.

Aug 2026 · Journal of Clinical Epidemiology · Vol 199, pp. 112442 · 0 citations
Medicine

TL;DR

This pilot study provides promising insights for improving the costs and duration of clinical trials by combining experimental arms with specialized cancer registry data.

Abstract

Background

Randomized clinical trials are becoming very challenging to perform in oncology both in rare cancers and in more common cancers, fragmented according to molecular characteristics.

Objective

In this proof of concept, we tested the feasibility of using data from a specialized digestive cancer registry as an external control arm in two phase III randomized clinical trials.

Methods

To emulate PETACC-8, the generated hybrid control arm comprised a constrained proportion of external patients. PRODIGE-13 was emulated through a fully external control arm and through a hybrid control arm containing 50% of external patients. Propensity score was used either for inverse probability of treatment weighting or for patients matching. Absolute Standardized Mean Differences tested the balance between arms. Overall Survival was estimated using Kaplan-Meier estimator and compared using the Logrank test.

Results

For both trials, Registry data were considered fit-for-use despite different settings and patients baseline characteristics were balanced between the emulated trial arms. In the emulated PETACC-8 trial, the overall survivals of the hybrid control arms were not different from that of the control and experimental arms. In the emulation of PRODIGE-13, survival analyses showed that the fully external control arm mimicked the control arm and that the hybrid arm with 50% external data mimicked both control and experimental arms. Pending appropriate patient selection, the data from the Registry allowed to generate external control arms mimicking control arms.

Conclusion

This pilot study provides promising insights for improving the costs and duration of clinical trials by combining experimental arms with specialized cancer registry data.

Read PDF

Similar papers

Aug 2026

Reproducibility of overall survival in metastatic colorectal cancer randomized trials using ARCAD-Derived external control arms.

ARCAD-derived SCAs reliably reproduced control-arm OS and benchmark treatment-effect estimates from landmark RCTs in mCRC, and supports benchmarking, trial design, and exploratory analyses when conventional control arms are impractical.

M. Raeisi, T. André, Q. Shi et al. · 0 citations
Open access Sep 2026

Core Outcome Set Measures Are Underreported in Breast Cancer Randomized Clinical Trials: A Cross-Sectional Study.

INTRODUCTION Randomized controlled trials (RCTs) are the gold standard in oncology for the discovery of new therapeutic approaches and treatment management. As medicine takes a more patient-centered approach, patient-reported outcomes (PROs) have become imperative, particularly in clinical trials. The need for standard...

A. Douglas, Ty Moore, Griffin K. Hughes et al. · 0 citations
Open access Aug 2026

Prospective, longitudinal oncology registries enabling advanced real-world evidence: the iOMEDICO experience

Well-designed prospective, longitudinal registries collecting broad and deep real-world data complement RCTs, inform Health Technology Assessments, and fill knowledge gaps by creating treatment transparency, addressing evidence gaps, and providing realistic outcome expectations for the heterogeneous populations in rout...

M. Jänicke, S. Dille, M. Frank et al. · 0 citations
Open access Aug 2026

reFLASH: A proof-of-concept meta-analytic framework to validate surrogate endpoints in the absence of randomized clinical trial data.

BACKGROUND Within a meta-analytic framework, validating surrogate endpoints traditionally requires individual patient data (IPD) from multiple randomized controlled trials (RCTs). This is rarely feasible in rare and indolent diseases. We propose a proof-of-concept strategy that creates synthetic comparative evidence fr...

C. Bommier, J. Dixon, M. Maurer et al. · 0 citations
Open access Sep 2026

Trial Design, Endpoints and Results Reporting in Interventional Laryngeal Cancer Trials: A Registry-Based Analysis.

OBJECTIVES To characterize trial design, endpoint emphasis and public results reporting in interventional laryngeal cancer studies. DESIGN Registry-based descriptive study of trial records. SETTING ClinicalTrials.gov; records were retrieved on 28 July 2025. PARTICIPANTS Interventional trials retrieved using the t...

Jin Wang, Jun-Feng Wu, Zi-Qi Yang et al. · 0 citations
Sep 2026

Abstract A125: External Control Arms: a vital strategy to create high quality scientific evidence with patient centric trial design for pancreatic cancer trials in light of introduction of highly effective targeted therapies

AACR Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development The evolution of targeted therapies in pancreatic ductal adenocarcinoma (PDAC) may pose challenges for future clinical research. Assigning patients to standard-of-care chemotherapies in randomized controlled trials (...

Ruthie Davi · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.